KRAS P.G12C clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

    open to eligible people ages 18 years and up

    This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.

    at UC Irvine

Our lead scientists for KRAS P.G12C research studies include .

Last updated: